August 18, 2025CancersOpen Access

Maintenance Treatment with 5-Azacitidine in Patients with Acute Myeloblastic Leukemia Ineligible for Intensive Treatment and with Response After Induction Chemotherapy: A Phase II Clinical Trial

View Full Paper

Ask AI

Bookmark

Patients achieved a median overall survival of 11.5 months, indicating potential effectiveness of azacitidine in maintaining response after induction chemotherapy.
Progression-free survival was reported at 6.7 months, suggesting that 5-azacitidine can prolong remission for AML patients after initial treatment.
This single-arm Phase II trial assessed the effects of azacitidine on elderly AML patients who were ineligible for intensive therapy.
Significant improvements in daily function, cognitive function, and social function scores were observed, highlighting quality of life benefits for patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase II trial evaluates 5-azacitidine's impact on survival in acute myeloid leukemia patients unfit for intensive treatment, suggesting benefits in quality of life.

Cite This Study

Fernandez et al. (2025) studied this question.

synapsesocial.com/papers/68af2eeacf1dd9ea359e6ba3 https://doi.org/10.3390/cancers17162678

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial evaluates 5-azacitidine's impact on survival in acute myeloid leukemia patients unfit for intensive treatment, suggesting benefits in quality of life.

Maintenance Treatment with 5-Azacitidine in Patients with Acute Myeloblastic Leukemia Ineligible for Intensive Treatment and with Response After Induction Chemotherapy: A Phase II Clinical Trial

Key Points

Discussion

Implication

Cite This Study

Maintenance Treatment with 5-Azacitidine in Patients with Acute Myeloblastic Leukemia Ineligible for Intensive Treatment and with Response After Induction Chemotherapy: A Phase II Clinical Trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider